Application of tubeimoside in preparing medicine for treating special subtype leukemia

A special subtype, leukemia technology, applied in the field of medicine

Inactive Publication Date: 2018-09-21
SHAANXI UNIV OF SCI & TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The saponin is easily soluble in water and polar solvents, has good stability, and is suitable for making modern preparations such as tablets, capsules and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tubeimoside in preparing medicine for treating special subtype leukemia
  • Application of tubeimoside in preparing medicine for treating special subtype leukemia
  • Application of tubeimoside in preparing medicine for treating special subtype leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] Soil Fritillaria saponin C can be extracted from the soil Fritillaria bulbs by the following methods:

[0011] Crush the dried bulb of Fritillaria, sieve it, soak it with a certain amount of 5% ethanol several times, recover the ethanol under reduced pressure, and concentrate the extract until it has no alcohol smell. The fat was extracted and degreased with chloroform and n-hexane respectively, and the aqueous layer was lyophilized. The lyophilized powder was dissolved in water and separated by D101 ion exchange resin, and eluted with 30%, 70% and 100% ethanol respectively to obtain 3 fractions. Put the part eluted with 70% ethanol on a silica gel column, and elute it with a mixture of chloroform-methanol-water (7:3:1) to obtain Tubeimoside A and two other parts, one part of which is put on C 18 Reversed-phase silica gel column, eluted with 75% methanol solution to obtain the fritillary saponin B and another part; separate it by preparative HPLC, the mobile phase is 7...

Embodiment 2

[0013] CCK8 method to detect the growth inhibitory effect of fritillary saponin C on 8 kinds of leukemia cells

[0014] 2.1 Cell lines

[0015] Jurkat (acute T-cell leukemia), THP-1 (acute monocytic leukemia), L12010 (prolymphocytic leukemia), Dami (megakaryoblastic leukemia), EOL-1 (eosinophilic leukemia), RBL-1 ( Basic myeloid leukemia), MOLT-16 (adult T-cell leukemia), NCI-H929 (plasma cell leukemia). All cell lines were provided by the Affiliated Hospital of Guangdong Medical College. Cells were cultured in RPMI1640 medium containing 10% fetal bovine serum, penicillin 100U / L, streptomycin 100mg / L, 37°C, 5% CO 2 , cultured in a saturated humidity incubator, and the cells in the logarithmic growth phase were taken for experiments.

[0016] 2.2 Drugs

[0017] The imatinib solution and the fritillary saponin C solution were prepared with physiological saline, so that the final concentrations of the drugs were 1, 5, 10, 50, and 100 μmol / L.

[0018] 2.3 Test method

[0019...

Embodiment 3

[0023] Inhibition test on transplanted tumors of Dami cells in vivo Test drugs: Weigh out certain doses of fritillary saponin C and imatinib, respectively, and add normal saline to dissolve.

[0024] Administration route: intraperitoneal injection (ip).

[0025] Test animals: Dutch nude mice.

[0026] Cell line: megakaryocytic leukemia cell line (Dami), from the Affiliated Hospital of Guangdong Medical College.

[0027] Test method: 50 Dutch nude mice, weighing 18-22g. Both male and female. The Dami cell line 7-8 days after inoculation was diluted and counted at 1:10, so that the final concentration was 10 million leukemia cells / ml; 0.2ml (containing 2 million leukemia cells) was inoculated subcutaneously in the right armpit of each mouse. The next day, it was randomly divided into 5 groups: Tubeimoside C group (dose: 3mg / kg), Tubeimoside C group (dose: 8mg / kg), Tubeimoside C group (dose: 20mg / kg) blank Control group and imatinib (dose: 8mg / kg) positive control group. Tub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Hardnessaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of tubeimoside in preparing a medicine for treating special subtype leukemia. Pharmacodynamic tests show that tubeimoside separated and purified from bolbostemma paniculatum has a very remarkable function of inhibiting special subtype leukemia cell proliferation, meanwhile has a treatment function on common types of leukemia such as acute leukemia cell and chronic leukemia cell, and in addition has a good effect in inhibiting activity of subtype leukemia cells when being compared with that of a leukemia treatment medicine, namely Imatinib in the market.

Description

technical field [0001] The invention relates to the application of Tubeimoside III (CAS: 115810-13-4) in the preparation of medicines for treating special subtype leukemia, belonging to the technical field of medicine. technical background [0002] Leukemia is a malignant tumor of the hematopoietic system, commonly known as "blood cancer", and is one of the top ten high-incidence malignant tumors in China. The number of leukemia patients in my country is about 3 to 4 per 100,000 population. Among young adults and children under the age of 35, the incidence of acute leukemia is the highest, and it is the malignant tumor that causes the highest mortality rate among adolescents. Therefore, the research and treatment of leukemia is a very important direction now. The traditional treatment method is the application of cytotoxicity, interferon and allogeneic hematopoietic stem cell transplantation, which has great side effects. Hematopoietic stem cell transplantation is theoreti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/7048A61P35/02
CPCA61K31/704A61K31/7048A61P35/02
Inventor 梁承远鞠星可周军辉夏娟秦楠辛敏行史楷岐王学川
Owner SHAANXI UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap